Expansion to Support One of the Fastest Growing Pharmaceutical Markets in the World
NEW YORK, NY (PRWEB) APRIL 28, 2016
"QuickSTAT has seen a marked growth in clinical trial shipments to and from Latin American countries. To accommodate this growth, QuickSTAT has been making significant investments to enhance logistics capabilities in the region."
As part of an ongoing global expansion plan, QuickSTAT has made significant investments in recruiting top industry experts, and expanding its LATAM network and logistics capabilities. Enhancements have been made to its IT Platform, which provides industry-leading tools for clients to manage their clinical trial projects.
The expansion will provide unmatched clinical trial logistics services for the pharmaceutical and biotech companies conducting clinical trials in the region.
Since 2008, Latin America has been one of the fastest growing pharmaceutical markets in the world, driven by generic drugs manufactured by local companies and biosimilars manufactured both by multinational and local pharmaceutical companies.
QuickSTAT has seen a marked growth in clinical trial and clinical trial supply shipments shipments to and from Latin American countries. To accommodate this growth, QuickSTAT has been making significant investments to enhance logistics capabilities in the region. Highlights include:
“Our investment in an increased global footprint in Latin America, the recruitment of top industry specialists, along with our market-leading IT platform demonstrates our commitment to the Life Science community in the region. We are very excited about the enhanced solutions and tools we can provide ” says Dominique Brown, COO, QuickSTAT.
For over 35 years, QuickSTAT has managed multinational biopharmaceutical clinical trial logistics for all phases of research and drug development, for all temperature ranges and life science products. QuickSTAT specializes in time and temperature shipping of clinical research samples, biologics, investigational drugs, clinical trial supplies, vaccines and dangerous goods, helping to bring important new drugs and medical protocols to market faster.